26309-99-9

Usage

Uses

Used in Organic Synthesis:
6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine is used as a key intermediate in organic synthesis for the production of various chemical compounds.
Used in Pharmaceutical Industry:
6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine is used as a building block for the preparation of pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine is used as an intermediate in the production of agrochemicals, aiding in the creation of effective pesticides and other agricultural products.

Upstream product

• 39270-39-8 (2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanol 
• 3943-89-3 Ethyl protocatechuate 
• 20825-87-0 2,3-dihydrobenzo[1,4]dioxine-6-carboxylic acid ethyl ester 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 493-09-4 benzo-1,4-dioxane 
• 50-00-0 formaldehyd 

Downstream Products

• 80985-34-8 6,7-bis(chloromethyl)-1,4-benzodioxan 
• 1026563-23-4 [2-cyano-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethoxy)-phenoxy]-o-tolyl-acetic acid methyl ester 
• 1147564-46-2 (PhMe(C₈H₇O₂CH₂)P)BH₃ 
• 166519-76-2 (2S,4R)-2-[(S)-1-(Benzyl-methyl-carbamoyl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethylcarbamoyl]-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 158574-76-6 [(S)-1-(Benzyl-methyl-carbamoyl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS

Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Synthesis of isoquinolines and tetrahydroisoquinolines as potential antitumour agents

The isoquinoline 17 and the tetrahydroisoquinoline 16 were synthesized from 2,3-dihydro-1,4-benzodioxin (1) by different synthetic strategies. Preparation of arylethylamines and their cyclization in Bischler-Napieralski conditions have been studied. Another approach to isoquinolines was based on the amination of the ketone 13 followed by cyclization in acidic media. The route via the amide 15 was found to be more successful with respect to both yield and ease of reaction.

FURAN DERIVATIVES HAVING ANTI-ULCER ACTIVITY

Compounds of formula (I): STR1 wherein: A represents a CH-NO 2 group or a N-CN group;B represents CH 2, O, S or a direct bond;R represents a bicyclic or polycyclic residue, variously substituted and functionalized;R 1 and R 2, which may be the same or different, are hydrogen or C 1-C 4 alkyl groups; andn and m, which may be the same or different, are 0, 1, 2, 3 or 4; are valuable pharmacological agents.